/
ALMS
$27.14+$0.74 (+2.80%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$3.4B
127M shares
52-week range
$2.92 – $30.60
88% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.39%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$13.84
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $24.1M |
| Cost of revenue | $250.0K | $0 | $3.2M | $3.5M |
| Gross profit | −$250.0K | $0 | −$3.2M | $20.6M |
| Gross margin | — | — | — | 85.5% |
| R&D | $101.1M | $137.7M | $265.6M | $386.0M |
| Operating income | −$113.8M | −$158.2M | −$300.8M | −$427.2M |
| EBITDA | −$111.7M | −$153.7M | −$291.1M | −$248.4M |
| Net income | −$111.9M | −$155.0M | −$294.2M | −$243.3M |
| Net margin | — | — | — | -1011.7% |
| EPS (diluted) | -14.93 | -2.99 | -10.38 | -2.32 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $8M | $-2.86 | $-3.15–$-2.59 | 7 |
| 2027 | $26M | $-2.73 | $-3.05–$-2.25 | 6 |
| 2028 | $169M | $-1.86 | $-2.69–$-0.96 | 6 |
| 2029 | $427M | $-0.81 | $-1.70–$-0.07 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.13
Price
$27.14
Implied downside
-96%
Peer comparison
Alumis Inc. Common Stock
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
www.alumis.com- Employees
- 227
- IPO / List date
- Jun 28, 2024
- HQ
- SOUTH SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds ALMS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 75,167 | $1.7M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ALMS yet.
